Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Revelation Biosciences Inc.
Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds
August 21, 2024
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)
March 13, 2024
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference
March 12, 2024
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
March 04, 2024
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
February 13, 2024
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering
February 05, 2024
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering
February 01, 2024
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
January 30, 2024
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024
January 23, 2024
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies
October 12, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference
October 04, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors
October 02, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023
August 11, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders
June 29, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal
June 12, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress
May 22, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Revelation Biosciences Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Recent Corporate Progress
March 30, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board
March 13, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Revelation Biosciences Inc. to Participate in a Fireside Chat at the 35th Annual Roth Conference
March 06, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Revelation Biosciences Inc. Announces Closing of $15.6 Million Public Offering
February 13, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Revelation Biosciences Inc. Announces Pricing of $15.6 Million Public Offering
February 09, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300
February 07, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Revelation Biosciences Inc. Announces 1-for-35 Reverse Stock Split effective February 1, 2023 and Results of Special Meeting of Stockholders
January 31, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Revelation Biosciences Inc. Announces Mandatory Unit Separation to Occur on January 13, 2023
January 10, 2023
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model
November 18, 2022
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Revelation Biosciences Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Recent Corporate Progress
November 10, 2022
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Revelation Biosciences Inc. Announces Positive Results in Preclinical Model of Acute and Chronic Kidney Disease
October 25, 2022
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Revelation Biosciences Inc. and Vanderbilt University Enter Exclusive Worldwide License Agreement
October 06, 2022
From
Revelation Biosciences Inc.
Via
Business Wire
Tickers
REVB
Revelation Biosciences Inc. to Present at 2021 BIO Digital Conference
June 09, 2021
From
Revelation Biosciences Inc.
Via
Business Wire
Revelation Biosciences Inc. Announces Results of Phase 1 Clinical Study of REVTx‑99, an Experimental Therapy for the Prevention of Respiratory Viral Infection
May 05, 2021
From
Revelation Biosciences Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.